Published in N Engl J Med on October 31, 2004
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest (2008) 3.11
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev (2015) 2.19
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia (2011) 1.80
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol (2012) 1.75
Oxidative stress in diabetic nephropathy. Curr Med Chem (2010) 1.70
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res (2013) 1.42
Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol (2012) 1.42
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol (2009) 1.29
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One (2013) 1.16
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials. J Am Board Fam Med (2007) 1.13
Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes (2009) 1.09
Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy. J Investig Med (2013) 1.09
Choice of first antihypertensive--comparison between the Irish and Dutch setting. Br J Clin Pharmacol (2008) 1.07
Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes (2009) 1.05
Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc (2012) 1.04
Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens (2008) 1.03
B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. J Am Soc Nephrol (2015) 1.02
Misdiagnosis and mistreatment of a common side-effect--angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol (2010) 1.01
Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis (2014) 1.01
Reduction in basal nitric oxide activity causes albuminuria. Diabetes (2011) 1.01
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol (2011) 1.01
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol (2008) 0.99
Angiotensin receptors as determinants of life span. Pflugers Arch (2009) 0.97
Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial. PLoS One (2015) 0.96
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia (2009) 0.95
Microalbuminuria, is it so important? Hippokratia (2007) 0.94
Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Med (2010) 0.93
Diabetic nephropathy in American Indians, with a special emphasis on the Pima Indians. Curr Diab Rep (2008) 0.92
Hepatitis C virus and its renal manifestations: a review and update. Gastroenterol Hepatol (N Y) (2012) 0.92
Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) (2008) 0.92
Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag (2009) 0.92
Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. CMAJ (2005) 0.92
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens (2012) 0.91
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag (2009) 0.90
The kallikrein-kinin system in diabetic nephropathy. Kidney Int (2012) 0.90
Therapeutic management of diabetic kidney disease. J Diabetes Investig (2011) 0.90
Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. Am J Pathol (2013) 0.90
Early detection and management of the high-risk patient with elevated blood pressure. Vasc Health Risk Manag (2008) 0.90
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol (2011) 0.87
Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care (2012) 0.87
Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease. Clin Exp Nephrol (2006) 0.85
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
Electronic problem list documentation of chronic kidney disease and quality of care. BMC Nephrol (2014) 0.84
New perspectives in the renin-angiotensin-aldosterone system (RAAS) I: endogenous angiotensin converting enzyme (ACE) inhibition. PLoS One (2014) 0.84
Present and future in the treatment of diabetic kidney disease. J Diabetes Res (2015) 0.84
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control (2009) 0.83
Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care (2008) 0.83
Diabetes: Which risk engines should be used to assess patients with diabetes? Nat Rev Endocrinol (2009) 0.83
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res (2009) 0.83
Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev (2007) 0.83
Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial. J Ophthalmol (2010) 0.83
Arterial hypertension in diabetes mellitus: from theory to clinical practice. Hippokratia (2008) 0.82
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol (2013) 0.82
Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol (2008) 0.81
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes (2013) 0.81
The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hypertens Res (2015) 0.81
New perspectives in the renin-angiotensin-aldosterone system (RAAS) III: endogenous inhibition of angiotensin converting enzyme (ACE) provides protection against cardiovascular diseases. PLoS One (2014) 0.80
Evidence-based approach for managing hypertension in type 2 diabetes. Integr Blood Press Control (2010) 0.80
Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination. Vasc Health Risk Manag (2007) 0.80
The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis Tissue Repair (2010) 0.80
Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors. Am J Kidney Dis (2009) 0.80
Treating diabetic nephropathy--are there only economic issues? N Engl J Med (2004) 0.80
Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathways. PLoS One (2014) 0.79
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab (2017) 0.79
RAS blockade for every diabetic patient: pro and con. Diabetes Care (2011) 0.79
Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract (2014) 0.79
The natural course of microalbuminuria among African Americans with type 2 diabetes: a 3-year study. Am J Med (2009) 0.79
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.79
Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study. BMC Endocr Disord (2013) 0.79
[Diabetic nephropathy--update 2012]. Wien Klin Wochenschr (2012) 0.79
Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS One (2013) 0.79
Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. Can J Cardiol (2007) 0.78
Manidipine-delapril combination in the management of hypertension. Vasc Health Risk Manag (2007) 0.78
Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes. F1000 Med Rep (2010) 0.78
Cardiac autonomic neuropathy as a predictor of deterioration of the renal function in normoalbuminuric, normotensive patients with type 2 diabetes mellitus. J Korean Med Sci (2009) 0.78
Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol (2011) 0.78
Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med (2008) 0.78
Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis. Biosci Rep (2016) 0.77
Cause-specific mortality according to urine albumin creatinine ratio in the general population. PLoS One (2014) 0.77
When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. Pediatr Nephrol (2010) 0.77
Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros? Diabetes Care (2009) 0.77
Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease? BMC Pharmacol Toxicol (2015) 0.77
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Long-term outcome of renal transplantation from older donors. N Engl J Med (2006) 5.10
A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy. Eur J Anaesthesiol (2012) 4.73
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int (2003) 1.91
Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J Am Soc Nephrol (2008) 1.89
STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol (2012) 1.89
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit. J Am Soc Nephrol (2010) 1.85
Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care (2012) 1.85
An image-based modeling framework for patient-specific computational hemodynamics. Med Biol Eng Comput (2008) 1.84
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol (2003) 1.81
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int (2013) 1.81
In vivo maturation of functional renal organoids formed from embryonic cell suspensions. J Am Soc Nephrol (2012) 1.81
Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol (2005) 1.79
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol (2007) 1.76
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol (2012) 1.75